Survival of corneal allografts following topical treatment with the immunomodulator mycophenolate mofetil

Ophthalmologica

Volumn 224, Issue 1, 2009, Pages 38-41

  Bertelmann, Eckart ^a   De Ruijter, Maurice ^a   Gong, Nianqiao ^a   Knapp, Sigrid ^b   Pleyer, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Corneal surgery; Corneal transplantation; Drug delivery; Experimental surgery

Indexed keywords

BETA CYCLODEXTRIN; IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; KERATOPLASTY; LEWIS RAT; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; POSTOPERATIVE PERIOD; RAT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ANIMALS; BETA-CYCLODEXTRINS; CORNEAL TRANSPLANTATION; DISEASE MODELS, ANIMAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; OPHTHALMIC SOLUTIONS; RATS; RATS, INBRED LEW; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 68349085668     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233237     Document Type: Article

References (13)

1. Reis A, Reinhardt T, Voiculescu A, Kutkuhn B, Godehardt E: Effect of mycophenolate mofetil versus cyclosporin A in high-risk keratoplasty patients: a prospective randomized clinical trial. Br J Ophthalmol 1999; 83: 1268-1271.
2. Reinhard T, Mayweg S, Sokolovska Y, Seitz B, Mittelviefhaus H, Engelmann K, Voiculescu A, Godehardt E, Sundmacher R: Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transpl Int 2005; 18: 703-708.
3. Bertelmann E, Reinhard T, Pleyer U: Current practice of immune prophylaxis and therapy in perforating keratoplasty: a survey of members of the Cornea Section of the German Ophthalmological Society. Ophthalmologe 2003; 100: 1031-1035.
4. Algros MP, Angonin R, Delbosc B, Cahn JY, Kantelip B: Danger of systemic cyclosporine for corneal graft. Cornea 2002; 21: 613-614.
5. Pleyer U, Lutz S, Jusko WJ, Nguyen K, Narawane M, Rückert D, Mondino BJ, Lee VHL: Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci 1993; 34: 2737-2743.
6. Bertelmann E, Pleyer U: Immunomodulatory therapy in ophthalmology - is there a place for topical application? Ophthalmologica 2004; 218: 359-367.
7. Bertelmann E, Knapp S, Rieck P, Keipert S, Hartmann C, Pleyer U: Transkornealerparakornealer Penetrationsweg für lokal applizierte Pharmaka am Auge: Mycophenolat Mofetil als Modellsubstanz. Ophthalmologe 2003; 100: 696-701.
8. Knapp S, Bertelmann E, Hartmann C, Keipert S, Pleyer U: Intraocular availability of topically applied mycophenolate mofetil in rabbits. J Ocul Pharmacol Ther 2003; 19: 181-192.
9. Gill TJ, Kunz HW, Misra DN, Hassett ALC: The major histocompatibility complex of the rat. Transplantation 1987; 43: 773-785.
10. Pleyer U: Immunobiology and prevention of allograft reaction after experimental keratoplasty. Buren, Aeolus, 1996, pp 22-23.
11. Pleyer U, Milani JK, Dukes A, Chou J, Lutz S, Rückert D, Thiel HJ, Mondino BJ: Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci 1995; 35: 52-61.
12. Reis A, Reinhard T, Sundmacher R, Braunstein C, Godehard E: Effect of mycophenolate mofetil, cyclosporine A and both in combination in a murine corneal graft rejection model. Br J Ophthalmol 1998; 82: 700-703.
13. Bertelmann E, Jaroszewski J, Pleyer U: Corneal allograft rejection: current understanding. 2. Clinical implications. Ophthalmologica 2002; 216: 2-12.